LNTH News and Press, Lantheus Holdings Inc. From 07/30/20

Completed acquisition of Progenics Pharmaceuticals, Inc., adding robust portfolio of oncology therapeutics and diagnostics to pipeline Worldwide revenue of $66.0 million for the second quarter 2020, representing a decrease of 23.0% from the prior year period Net loss of $7.0 ...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, July 30, 2020, to discuss its financial and operating results for the second quarter of 2020. To access the live conference call via tele...

This article series has been releasing every month since 2015 a dashboard with aggregate industry metrics in healthcare (most popular ETFs in this sector: XLV , IYH , IBB , XBI , VHT , XPH ). Shortcut If you are used to this dashboard series or if you are short of time, you can s...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and product...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it...

Merger activity decreased last week with two new deals announced, and one deal closing. One of the two new deals announced last week was on our list of potential deals and the other one was a "going private" transaction. According to Reuters, Australian antitrust regulators expressed conc...

NEW YORK , June 17, 2020 /PRNewswire/ -- Independent Bank Group Inc. (NASD: IBTX) will replace Progenics Pharmaceuticals Inc. (NASD: PGNX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, June 22 . S&P Small-Cap 600 constituent Lantheus Holdings I...

Lantheus Holdings (NASDAQ: LNTH ) shareholders voted overwhelmingly in favor of issuing common stock related to its previously announced merger with Progenics Pharmaceuticals (NASDAQ: PGNX ). 99% of the votes cast backed the plan. More news on: Lantheus Holdings, Inc., Progenics Pharmace...

Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents announced that at a ...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mar...